Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status (Q27853066)

PubMed publication ID

25212276

13 November 2016

title

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status (English)

1 reference

PubMed publication ID

25212276

13 November 2016

main subject

chronic myeloid leukemia

0 references

0 references

1 reference

A Hochhaus

13

0 references

Torsten Haferlach

11

object named as

T Haferlach

0 references

Claudia Haferlach

12

object named as

C Haferlach

0 references

Susanne Schnittger

4

object named as

S Schnittger

0 references

author name string

M Schmidt

1

0 references

J Rinke

2

0 references

V Schäfer

3

0 references

A Kohlmann

5

0 references

E Obstfelder

6

0 references

C Kunert

7

0 references

J Ziermann

8

0 references

N Winkelmann

9

0 references

E Eigendorff

10

0 references

T Ernst

Chronic myeloid leukaemia

14

0 references

publication date

December 2014

0 references

published in

Leukemia

0 references

volume

28

0 references

issue

12

0 references

page(s)

2292-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Clonal architecture of secondary acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Predicting the functional effect of amino acid substitutions and indels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

A method and server for predicting damaging missense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

The role of mutations in epigenetic regulators in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Dnmt3a is essential for hematopoietic stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Minimal Residual Disease after Bone Marrow Transplant for Chronic Myeloid Leukaemia Detected by the Polymerase Chain Reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.272

Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis

21 January 2018

1 reference

12 December 2020

Evidence for a multistep pathogenesis of chronic myelogenous leukemia

1 reference

12 December 2020

Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib

1 reference

12 December 2020

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

1 reference

12 December 2020

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

1 reference

12 December 2020

Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia

1 reference

12 December 2020